Effects of the flaxseed lignans secoisolariciresinol diglucoside and its aglycone on serum and hepatic lipids in hyperlipidaemic rats

British Journal of Nutrition

Volumn 102, Issue 3, 2009, Pages 361-369

  Felmlee, M A ^a   Woo, G ^b   Simko, E ^c   Krol, E S ^d   Muir, A D ^e   Alcorn, J ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e AGRICULTURE AND AGRI FOOD CANADA   (Canada)

Author keywords

Hyperlipidaemia; Purified flaxseed lignans; Rats

Indexed keywords

AGLYCONE; FATTY ACID; FRUCTOSE; LIGNAN DERIVATIVE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PHOSPHOLIPID; SECOISOLARICIRESINOL DIGLUCOSIDE; UNCLASSIFIED DRUG; BUTANEDIOL; GLUCOSIDE; LIGNAN; SECOISOLARICIRESINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; HISTOLOGY; HOMEOSTASIS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LINSEED; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID STORAGE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; TREATMENT DURATION; WEIGHT GAIN; ANIMAL; BLOOD; BODY WEIGHT; CHEMISTRY; DIET THERAPY; DOSE RESPONSE; FLAX; LIVER; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; WISTAR RAT;

RATTUS;

ANIMALS; BASE SEQUENCE; BODY WEIGHT; BUTYLENE GLYCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAX; FRUCTOSE; GENE EXPRESSION; GLUCOSIDES; HYPERLIPIDEMIAS; LIGNANS; LIPIDS; LIVER; MALE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 70149102666     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508207488     Document Type: Article

References (30)

1. Bestermann W, Houston MC, Basile J, et al. (2005) Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 329, 292-305.
2. Bloedon LT & Szapary PO (2004) Flaxseed and cardiovascular risk. Nutr Rev 62, 18-27.
3. Fukumitsu S, Aida K, Ueno N, et al. (2008) Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br J Nutr 100, 669-676.
4. Prasad K (2007) A study on regression of hypercholesterolemic atherosclerosis in rabbits by flax lignan complex. J Cardiovasc Pharmacol Ther 12, 304-313.
5. Ratnayake WM & Gilani GS (2003) Protective effects of flax meal against hypercholesterolemia and hypertriglyceridemia in rats. J Am Coll Nutr 22, 157-164.
6. Prasad K (2005) Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 179, 269-275. (Pubitemid 40364620)
7. Jenkins DJ, Kendall CW, Vidgen E, et al. (1999) Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 69, 395-402.
8. Lucas EA, Wild RD, Hammond LJ, et al. (2002) Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 87, 1527-1532.
9. Hall C III & Tulbek MC Xu Y (2006) Flaxseed. Adv Food Nutr Res 51, 1-97.
10. Pan A, Sun J, Chen Y, et al. (2007) Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS ONE 2, e1148.
11. Zhang W, Wang X, Liu Y, et al. (2008) Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr 99, 1301-1309.
12. Axelson M, Sjovall J, Gustafsson BE, et al. (1982) Origin of lignans in mammals and identification of a precursor from plants. Nature 298, 659-660.
13. Hu C, Yuan YV & Kitts DD (2007) Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro. Food Chem Toxicol 45, 2219-2227.
14. Bhathena SJ & Velasquez MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76, 1191-1201.
15. Kushiro M, Masaoka T, Hageshita S, et al. (2002) Comparative effect of sesamin and episesamin on the activity and gene expression of enzymes in fatty acid oxidation and synthesis in rat liver. J Nutr Biochem 13, 289-295.
16. Martin G, Duez H, Blanquart C, et al. (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin Invest 107, 1423-1432.
17. Mezei O, Banz WJ, Steger RW, et al. (2003) Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133, 1238-1243.
18. Schoonjans K, Staels B & Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37, 907-925.
19. Friedewald WT, Levy RI & Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.
20. Roglans N, Sanguino E, Peris C, et al. (2002) Atorvastatin treatment induced peroxisome proliferator-activated receptor a expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302, 232-239.
21. Shimomura I, Hammer RE, Richardson JA, et al. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12, 3182-3194.
22. Bierenbaum ML, Reichstein R & Watkins TR (1993) Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation: a preliminary report. J Am Coll Nutr 12, 501-504.
23. Prasad K (1999) Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99, 1355-1362.
24. Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2, 282-286.
25. Bhathena SJ, Ali AA, Haudenschild C, et al. (2003) Dietary flaxseed meal is more protective than soy protein concentrate against hypertriglyceridemia and steatosis of the liver in an animal model of obesity. J Am Coll Nutr 22, 157-164.
26. Prasad K, Mantha SV, Muir AD, et al. (1998) Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low a-linolenic acid. Atherosclerosis 136, 367-375.
27. Lemay A, Dodin S, Kadri N, et al. (2002) Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 100, 495-504.
28. Cunnane SC, Ganguli S, Menard C, et al. (1993) High a-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr 69, 443-453.
29. Gowri MS, Reaven GM & Azhar S (1999) Masoprocol lowers blood pressure in rats with fructose-induced hypertension. Am J Hypertens 12, 744-746.
30. Hemmings SJ & Barker L (2004) The effects of dietary flaxseed on the Fischer 344 rat: I. Development, behaviour, toxicity and the activity of liver g-glutamyltranspeptidase. Cell Biochem Funct 22, 113-121.